GlassScriptPhysician profile
Mussie Beraki
NPI 1679898969
$1,017.20
in general payments reported to CMS, 2019-2025
11 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2022: $263 · 2023: $153 · 2024: $210 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $649.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $253.00 | 2022-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $166.92 | 2022-2023 | Farxiga |
| Ardelyx, INC. | $121.86 | 2024 | Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $104.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.72 | 2024-2025 | Jardiance, Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $67.37 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $65.91 | 2024-2025 | |
| Travere Therapeutics, INC. | $47.84 | 2023 | |
| Aurinia Pharma U.S., INC. | $43.39 | 2023-2025 | Lupkynis |
| Amgen INC. | $41.33 | 2024-2025 | Tavneos, Krystexxa |
| Ani Pharmaceuticals, INC. | $33.52 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mussie Beraki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.